Carotid Intima-Media Thickness and Liver Histology in Hemodialysis Patients with Nonalcoholic Fatty Liver Disease

ABSTRACT

The prevalence of atherosclerotic cardiovascular disease in chronic hemodialysis (HD) patients has been demonstrated to be higher than in healthy people. Severe liver fibrosis is strongly associated with early carotid atherosclerosis and it might reduce the survival of patients who undergo both renal replacement therapy and transplantation. We wanted to assess whether nonalcoholic fatty liver disease (NAFLD) was associated with altered intima-media thickness (IMT) in HD patients as an independent marker of subclinical atherosclerosis. We enrolled 42 patients undergoing HD and 48 patients with normal renal function, all of them with high levels of aminotransferases and an ultrasonographic diagnosis of liver steatosis. The control group consisted of 60 healthy subjects. Laboratory tests for inflammatory and oxidative markers, ultrasonographic liver evaluation, carotid IMT measurement, and liver biopsy were performed. Different degrees of fibrosis were detected in our study cohort. Worse liver histopathological scores and higher plasmatic levels of C-reactive protein, reactive oxygen species, and vascular cell adhesion molecule-1 were found in HD patients. Carotid IMT was significantly higher (p < 0.005) in patients with histological steatosis. HD patients may develop active and progressive chronic hepatitis faster than patients with normal renal function and the thickness of their carotid intima-media might be markedly increased. These two conditions seem to be independent on classical risk factors and on metabolic syndrome. They might be related to the high levels of oxidants and to the inflammatory state, which are typical of patients undergoing HD. Independently related with the traditional risk factors for cardiovascular disease, nonspecific inflammation and oxide-reductive imbalance may play an important role in the progression of NAFLD and atherosclerotic disease in HD patients.

Chronic hepatitis - nonalcoholic steatohepatitis - oxidative stress - fibrosis - intima-media thickness - hemodialysis

REFERENCES

• 1 Cheung A K, Sarnak M J, Yan G et al.. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients.  Kidney Int. 2000;  58 (1) 353-362
• 2 Angulo P. Nonalcoholic fatty liver disease.  N Engl J Med. 2002;  346 (16) 1221-1231
• 3 Clark J M, Brancati F L, Diehl A M. Nonalcoholic fatty liver disease.  Gastroenterology. 2002;  122 (6) 1649-1657
• 4 Adinolfi L E, Gambardella M, Andreana A, Tripodi M F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.  Hepatology. 2001;  33 (6) 1358-1364
• 5 Targher G, Bertolini L, Padovani R et al.. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.  Diabetes Care. 2006;  29 (6) 1325-1330
• 6 Benedetto F A, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients.  J Am Soc Nephrol. 2001;  12 (11) 2458-2464
• 7 Nishizawa Y, Shoji T, Maekawa K et al.. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients.  Am J Kidney Dis. 2003;  41 (3, Suppl 1) S76-S79
• 8 Kleiner D E, Brunt E M, Van Natta M et al.. Design and validation of a histological scoring system for non alcoholic fatty liver disease.  Hepatology. 2005;  4 1313-1321
• 9 Brunt E M. Nonalcoholic steatohepatitis.  Semin Liver Dis. 2004;  24 (1) 3-20
• 10 American Diabetes Association . Diagnosis and classification of diabetes mellitus.  Diabetes Care. 2004;  27 (Suppl 1) S5-S10
• 11 Macy E M, Hayes T E, Tracy R P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications.  Clin Chem. 1997;  43 (1) 52-58
• 12 Fiotti N, Giansante C, Ponte E et al.. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease.  Atherosclerosis. 1999;  145 (1) 51-60
• 13 Yagi K. Assay for serum lipid peroxide level and its chemical significance. In: Yagi K, ed. Lipid Peroxides in Biology and Medicine. New York: Academic Press; 1982: 223-242
• 14 Esterbauer H, Cheeseman K H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal.  Methods Enzymol. 1990;  186 407-421
• 15 Paglia D E, Valentine W N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.  J Lab Clin Med. 1967;  70 (1) 158-169
• 16 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 (7) 412-419
• 17 Haffner S M, Miettinen H, Stern M P. The homeostasis model in the San Antonio Heart Study.  Diabetes Care. 1997;  20 (7) 1087-1092
• 18 World Health Organization .AUDIT. The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. Genève, Switzerland: WHO; 1992
• 19 O'Leary D H, Polak J F. Intima-media thickness: a tool for atherosclerosis imaging and event prediction.  Am J Cardiol. 2002;  90 (10C) 18L-21L
• 20 Cortez-Pinto H, de Moura M C, Day C P. Non-alcoholic steatohepatitis: from cell biology to clinical practice.  J Hepatol. 2006;  44 (1) 197-208
• 21 Targher G, Bertolini L, Padovani R et al.. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease.  Diabet Med. 2006;  23 (4) 403-409
• 22 Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C.  J Hepatol. 2007;  46 (6) 1126-1132
• 23 Stenvinkel P, Heimbürger O, Paultre F et al.. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.  Kidney Int. 1999;  55 (5) 1899-1911
• 24 Chen J, Muntner P, Hamm L L et al.. The metabolic syndrome and chronic kidney disease in U.S. adults.  Ann Intern Med. 2004;  140 (3) 167-174
• 25 Seki S, Kitada T, Sakagushi H, Katani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease.  J Hepatol. 2002;  37 (1) 56-62
• 26 Chalasani N, Deeg M A, Crabb D W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis.  Am J Gastroenterol. 2004;  99 (8) 1497-1502
• 27 Volzke H, Robinson D M, Kleine V et al.. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis.  World J Gastroenterol. 2005;  11 (12) 1848-1853
• 28 Bressler P, Bailey S R, Matsuda M, DeFronzo R A. Insulin resistance and coronary artery disease.  Diabetologia. 1996;  39 (11) 1345-1350